Ela2 mutations and clinical manifestations in familial congenital neutropenia

Area of Science:

• Hematology
• Genetics
• Immunology

Background:

• Severe congenital neutropenia (SCN) and cyclic neutropenia (CN) are rare genetic disorders characterized by recurrent infections due to low neutrophil counts.
• The neutrophil elastase (Ela2) gene plays a crucial role in neutrophil function and is implicated in the pathogenesis of these neutropenias.

Purpose of the Study:

• To investigate Ela2 gene mutations in familial and sporadic cases of SCN and CN.
• To analyze the levels of neutrophil-specific granule proteins, cathelicidin antimicrobial peptide and neutrophil gelatinase-associated lipocalin, in SCN patients.
• To evaluate the effectiveness of prophylactic treatments and age-related infection frequency in patients with Ela2 mutations.

Main Methods:

• Genomic DNA was extracted from patient samples (peripheral blood or bone marrow).
• The coding sequence of the Ela2 gene was amplified via polymerase chain reaction and analyzed using direct sequencing.
• Neutrophil antimicrobial peptide content was quantified using flow cytometry.

Main Results:

• Heterozygous mutations in the Ela2 gene were identified in familial SCN, familial CN, and sporadic SCN cases. A novel Ela2 mutation (W212stop) was found in a familial CN case.
• Prophylactic treatment with growth factors or antibiotics proved beneficial in reducing infectious episodes.
• Adult patients experienced fewer infections than pediatric patients within the same family.
• Levels of cathelicidin antimicrobial peptide and neutrophil gelatinase-associated lipocalin were significantly decreased in SCN patients compared to healthy controls.

Conclusions:

• Prophylaxis with growth factors or antibiotics is effective in mitigating the risk of bacterial infections in SCN and CN.
• Adults with SCN and CN carrying the same Ela2 mutation tend to have a lower incidence of infections compared to children.